TRACON Pharmaceuticals (NASDAQ:TCON) Downgraded by StockNews.com to “Hold”

StockNews.com cut shares of TRACON Pharmaceuticals (NASDAQ:TCONFree Report) from a buy rating to a hold rating in a research report report published on Saturday.

Separately, HC Wainwright decreased their target price on TRACON Pharmaceuticals from $120.00 to $60.00 and set a buy rating on the stock in a report on Wednesday, April 3rd.

Get Our Latest Analysis on TRACON Pharmaceuticals

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ:TCON opened at $1.43 on Friday. The stock has a market capitalization of $3.83 million, a price-to-earnings ratio of 2.13 and a beta of 1.28. The business’s fifty day moving average price is $4.36 and its two-hundred day moving average price is $3.91. TRACON Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $14.75.

TRACON Pharmaceuticals (NASDAQ:TCONGet Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.13). The company had revenue of $0.10 million for the quarter. During the same quarter in the prior year, the company posted ($7.20) earnings per share. Research analysts expect that TRACON Pharmaceuticals will post -4 EPS for the current fiscal year.

TRACON Pharmaceuticals Company Profile

(Get Free Report)

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.

Featured Articles

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.